■ 英語タイトル：Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
	■ 発行会社/調査会社：IMARC ■ 商品コード：IMARC23FB0121 ■ 発行日：2023年2月1日    最新版(2025年又は2026年)版があります。お問い合わせください。 ■ 調査対象地域：グローバル ■ 産業分野：医療機器 ■ ページ数：108 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール

The global allergy immunotherapies market size reached US$ 2.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2028, exhibiting a growth rate (CAGR) of 9.8% during 2023-2028.

Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a preventive medical treatment for allergic reactions to allergens including various foods, drugs, bee venom, grass pollens and house dust mites. It alters the immune system’s response by gradually increasing the doses of the allergen. Before the treatment begins, an allergist and patient analyze triggering factors for allergy symptoms, which may involve skin and blood tests to confirm the allergens. Allergy immunotherapy helps in reducing inflammation, offering long-term impact, increasing immunological tolerance, changing the course of the disease and improving the quality of the patient’s life.

In recent years, there has been a rise in the prevalence of allergies around the world on account of various environmental and lifestyle factors that influence the functioning of the immune system. With the growing awareness of allergy immunotherapies, elevating income levels and increasing healthcare expenditure, the demand for sophisticated and long-term treatment options is increasing, which in turn is stimulating the growth of the market. It is further supported by the rising clinical research and development budget owing to several initiatives undertaken by both governmental and non-governmental organizations around the world. Further, with the latest drug development technologies, pharmaceutical firms have created more efficient immunotherapies for treating an array of allergies successfully. This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global allergy immunotherapies market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on treatment type, allergy type and distribution channel.

Breakup by Treatment Type:

Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)

Breakup by Allergy Type:

Allergic Rhinitis
Asthma
Food Allergy
Venom Allergy
Others

Breakup by Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Breakup by Region:

Europe
North America
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG, etc.

Key Questions Answered in This Report
1. What was the size of the global allergy immunotherapies market in 2022?
2. What is the expected growth rate of the global allergy immunotherapies market during 2023-2028?
3. What are the key factors driving the global allergy immunotherapies market?
4. What has been the impact of COVID-19 on the global allergy immunotherapies market?
5. What is the breakup of the global allergy immunotherapies market based on the treatment type?
6. What is the breakup of the global allergy immunotherapies market based on the allergy type?
7. What is the breakup of the global allergy immunotherapies market based on the distribution channel?
8. What are the key regions in the global allergy immunotherapies market?
9. Who are the key players/companies in the global allergy immunotherapies market?